Evidence map›Paper›PMID 31544821›Full record

ArticleAntibodies (Basel, Switzerland)2019

Canine CD117-Specific Antibodies with Diverse Binding Properties Isolated from a Phage Display Library Using Cell-Based Biopanning.

Mohamed A Alfaleh, Neetika Arora, Michael Yeh, Christopher J de Bakker, Christopher B Howard, Philip Macpherson, Rachel E Allavena, Xiaoli Chen, Linda Harkness, Stephen M Mahler and 1 more

Open access · goldAbstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. C-kit, flt-3, PDGFR-β, and VEGFR2 expression in canine adrenal tumors and correlation with outcome following adrenalectomy.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2021
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Mohamed A AlfalehAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia. mohamed.alfaleh@uqconnect.edu.au.ORCID 0000-0003-3716-0019
Neetika AroraAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia. narora86@hotmail.com.
Michael YehAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia. uqmyeh@gmail.com.
Christopher J de BakkerAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia. chris.debakker@servatus.com.au.
Christopher B HowardAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia. c.howard2@uq.edu.au.
Philip MacphersonSchool of Veterinary Science, The University of Queensland, Gatton, QLD 4343, Australia. philip.macpherson@uq.net.au.
Rachel E AllavenaSchool of Veterinary Science, The University of Queensland, Gatton, QLD 4343, Australia. r.allavena@uq.edu.au.
Xiaoli ChenAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia. x.chen8@uq.edu.au.
Linda HarknessAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia. l.harkness@uq.edu.au.
Stephen M MahlerAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia. s.mahler@eng.uq.edu.au.
Martina L JonesAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia. martina.jones@uq.edu.au.ORCID 0000-0002-5154-6017
The University of Queensland · AUAustralian Research Council · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD117 (c-Kit) is a tyrosine kinase receptor that is overexpressed in multiple dog tumors. There is 100% homology between the juxtamembrane domain of human and canine CD117, and many cancer-causing mutations occur in this region in both species. Thus, CD117 is an important target for cancer treatment in dogs and for comparative oncology studies. Currently, there is no monoclonal antibody (mAb) specifically designed to target the exposed region of canine CD117, although there exist some with species cross-reactivity. We panned a naïve phage display library to isolate antibodies against recombinant CD117 on whole cells. Several mAbs were isolated and were shown to bind recombinant canine CD117 at low- to sub-nanomolar affinity. Additionally, binding to native canine CD117 was confirmed by immunohistochemistry and by flow cytometry. Competitive binding assays also identified mAbs that competed with the CD117 receptor-specific ligand, the stem cell factor (SCF). These results show the ability of our cell-based biopanning strategy to isolate a panel of antibodies that have varied characteristics when used in different binding assays. These in vitro/ex vivo assessments suggest that some of the isolated mAbs might be promising candidates for targeting overexpressed CD117 in canine cancers for different useful applications.

Indexed as

Affinity selectioncancercanineCD117c-Kitdogimmunohistochemistrymembrane proteinsmonoclonal antibodyphage displaysphere culturetransfectionveterinary oncologywhole cell panning

Identifiers

PMID31544821
PMCPMC6640692
OpenAlexW2911996141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.